000284366 001__ 284366
000284366 005__ 20260130153117.0
000284366 0247_ $$2doi$$a10.1007/s00702-025-02911-5
000284366 0247_ $$2pmid$$apmid:40121314
000284366 0247_ $$2ISSN$$a0375-9245
000284366 0247_ $$2ISSN$$a0022-3026
000284366 0247_ $$2ISSN$$a0300-9564
000284366 0247_ $$2ISSN$$a1435-1463
000284366 037__ $$aDZNE-2026-00134
000284366 041__ $$aEnglish
000284366 082__ $$a610
000284366 1001_ $$0P:(DE-2719)2810825$$aKoeglsperger, Thomas$$b0$$eFirst author$$udzne
000284366 245__ $$aReal-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.
000284366 260__ $$aWien [u.a.]$$bSpringer$$c2026
000284366 3367_ $$2DRIVER$$aarticle
000284366 3367_ $$2DataCite$$aOutput Types/Journal article
000284366 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769783246_7436$$xReview Article
000284366 3367_ $$2BibTeX$$aARTICLE
000284366 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284366 3367_ $$00$$2EndNote$$aJournal Article
000284366 520__ $$aTraditional advanced therapies in Parkinson's disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), levodopa-carbidopa entacapone intestinal gel (LECIG), or deep brain stimulation (DBS) have played a central role in managing therapy-related complications. Recently, continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) has emerged as a novel therapeutic option. This manuscript provides insights from one year of real-world experience with CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for advanced PD. Our discussion centers on key considerations for patient selection, exploring which individuals may benefit more from CSFLI compared to other device-aided therapies. We highlight CSFLI's advantages in flexibility and ease of use but also consider limitations, particularly its side effects, such as skin-related issues. Recommendations are presented on how to prevent and manage these adverse effects to maximize patient compliance and therapeutic success. Additionally, the paper examines strategies for optimizing concurrent oral medications when combined with CSFLI, providing guidance on balancing pump infusion with necessary adjunctive oral treatments.
000284366 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000284366 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000284366 650_7 $$2Other$$aAdvanced Treatment
000284366 650_7 $$2Other$$aFoslevodopa/Foscarbidopa
000284366 650_7 $$2Other$$aMotor Fluctuations
000284366 650_7 $$2Other$$aParkinson’s disease
000284366 650_7 $$2NLM Chemicals$$aAntiparkinson Agents
000284366 650_7 $$046627O600J$$2NLM Chemicals$$aLevodopa
000284366 650_7 $$0MNX7R8C5VO$$2NLM Chemicals$$aCarbidopa
000284366 650_7 $$2NLM Chemicals$$aDrug Combinations
000284366 650_7 $$2NLM Chemicals$$acarbidopa, levodopa drug combination
000284366 650_2 $$2MeSH$$aHumans
000284366 650_2 $$2MeSH$$aParkinson Disease: drug therapy
000284366 650_2 $$2MeSH$$aAntiparkinson Agents: administration & dosage
000284366 650_2 $$2MeSH$$aAntiparkinson Agents: adverse effects
000284366 650_2 $$2MeSH$$aLevodopa: administration & dosage
000284366 650_2 $$2MeSH$$aLevodopa: adverse effects
000284366 650_2 $$2MeSH$$aCarbidopa: administration & dosage
000284366 650_2 $$2MeSH$$aCarbidopa: adverse effects
000284366 650_2 $$2MeSH$$aDrug Combinations
000284366 650_2 $$2MeSH$$aInfusions, Subcutaneous
000284366 7001_ $$aBerberovic, Emir$$b1
000284366 7001_ $$aDresel, Christian$$b2
000284366 7001_ $$aHaferkamp, Sebastian$$b3
000284366 7001_ $$0P:(DE-2719)9001967$$aKassubek, Jan$$b4$$udzne
000284366 7001_ $$aMüller, Rahel$$b5
000284366 7001_ $$aOehlwein, Christian$$b6
000284366 7001_ $$aPaus, Sebastian$$b7
000284366 7001_ $$aUrban, Peter Paul$$b8
000284366 773__ $$0PERI:(DE-600)1481655-6$$a10.1007/s00702-025-02911-5$$gVol. 133, no. 2, p. 347 - 359$$n2$$p347 - 359$$tJournal of neural transmission$$v133$$x0375-9245$$y2026
000284366 8564_ $$uhttps://pub.dzne.de/record/284366/files/DZNE-2026-00134.pdf$$yRestricted
000284366 8564_ $$uhttps://pub.dzne.de/record/284366/files/DZNE-2026-00134.pdf?subformat=pdfa$$xpdfa$$yRestricted
000284366 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000284366 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001967$$aExternal Institute$$b4$$kExtern
000284366 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000284366 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-02$$wger
000284366 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-02$$wger
000284366 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURAL TRANSM : 2022$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000284366 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-02
000284366 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000284366 980__ $$ajournal
000284366 980__ $$aEDITORS
000284366 980__ $$aVDBINPRINT
000284366 980__ $$aI:(DE-2719)1111015
000284366 980__ $$aUNRESTRICTED